ImmunoDeficiency and ECMO for Acute respiratory failure
This study will provide, for the first time, detailed descriptive data on the characteristics, the complication and the outcome of adult's immunocompromised patients receiving ECMO for ARDS.
Assessment of ECMO in acute myocardial infarction with Non-reversible, Cardiogenic shock to Halt Organ failure & Reduce mortality.
This study is a prospective, open-label, multicenter, randomized, controlled trial including patients with ongoing myocardial ischemia complicated by cardiogenic shock with the intention to undergo early revascularization. The study goal is to determine if early VA-ECMO insertion in conjunction with optimal medical treatment is superior to optimal medical treatment alone after early revascularization.
Susan Tanzi Pfeifer, MBA
Director of Operations
Published on June 17, 2015